Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert HI; Michielin, Olivier; Olszanski, Anthony J; Malvehy, Josep; Cebon, Jonathan; Fernandez, Eugenio; Kirkwood, John M; Gajewski, Thomas F; Chen, Lisa; Gorski, Kevin S; Anderson, Abraham A; Diede, Scott J; Lassman, Michael E; Gansert, Jennifer; Hodi, F Stephen; Long, Georgina V (2018). Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 174(4):1031-1032.

Hamid, Omid; Puzanov, Igor; Dummer, Reinhard; Schachter, Jacob; Daud, Adil; Schadendorf, Dirk; Blank, Christian; Cranmer, Lee D; Robert, Caroline; Pavlick, Anna C; Gonzalez, Rene; Hodi, F Stephen; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Gangadhar, Tara C; Wei, Ziwen; Ebbinghaus, Scot; Ibrahim, Nageatte; Ribas, Antoni (2017). Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 86:37-45.

Izar, Benjamin; Sharfman, William; Hodi, F Stephen; Lawrence, Donald; Flaherty, Keith T; Amaravadi, Ravi; Kim, Kevin B; Puzanov, Igor; Sosman, Jeffrey; Dummer, Reinhard; Goldinger, Simone M; Lam, Lyhping; Kakar, Shefali; Tang, Zhongwen; Krieter, Oliver; McDermott, David F; Atkins, Michael B (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6(8):1904-1914.

Long, Georgina V; Weber, Jeffrey S; Larkin, James; Atkinson, Victoria; Grob, Jean-Jacques; Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Márquez-Rodas, Ivan; McNeil, Catriona; Schmidt, Henrik; Briscoe, Karen; Baurain, Jean-François; Hodi, F Stephen; Wolchok, Jedd D (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3(11):1511.

Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert H I; Michielin, Olivier; Olszanski, Anthony J; Malvehy, Josep; Cebon, Jonathan; Fernandez, Eugenio; Kirkwood, John M; Gajewski, Thomas F; Chen, Lisa; Gorski, Kevin S; Anderson, Abraham A; Diede, Scott J; Lassman, Michael E; Gansert, Jennifer; Hodi, F Stephen; Long, Georgina V (2017). Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 170(6):1109-1119.e10.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen; Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2016). Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19):1845-1855.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.

Weber, Jeffrey S; Dummer, Reinhard; de Pril, Veerle; Lebbé, Celeste; Hodi, F Stephen (2013). Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer, 119(9):1675-1682.

This list was generated on Sun Dec 16 08:58:21 2018 CET.